A Phase II Trial of R435(Bevacizumab) in chemotherapy naive and inoperable malignant pleural mesothelioma patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223239

Enrollment

Registered

2016-06-10

Start date

2016-07-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy naive and inoperable malignant pleural mesothelioma

Interventions

investigational material(s) Generic name etc : bevacizumab INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - ECOG Performance status 0 ot 2 - Histologically confirmed malignant pleural mesothelioma which is inoperable - chemotherapy naive (including pre or post operative adjuvant chemotherapy) - Identifiable tumor image present

Exclusion criteria

Exclusion criteria: - History of anti-tumor therapy(chemotherapy, Immunotherapy or biotherapy) - History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abcess in the last 6 months - Clinical symptoms accompanying or treatment requiring metastasis to central nervous system - History of cerebral vascular accident or transient ischemic attack in the last 6 months

Design outcomes

Primary

Measure	Time frame
other other (Tolerability) CTCAE (ver 4.03)	—

Secondary

Measure	Time frame
safety efficacy CTCAE ver 4.03, RECIST ver 1.1	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026